Altimmune, Inc. (ALT) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Altamune Year-End 2025 Financial Results Conference Call. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. As a reminder, this call is being recorded. I'll now introduce your host for today's conference call, Lee Roth, President of Burns McLellan, Investor Relations Advisor to Altimmune. Lee, you may begin. Thanks, Gigi, and good morning, everyone. Thank you for joining us for Altimmune's fourth quarter 2025 financial results and business update conference call. On today's call, you'll hear from Jerry Durso, our Chief Executive Officer, Dr. Christoph Arbett-Engels, Chief Medical Officer, Linda Richardson, Chief Commercial Officer, and Greg Weaver, Chief Financial Officer. Following management's prepared remarks, we'll open the line for the Q&A session. Our fourth quarter and full year 2025 earnings release was issued this morning and can be found on the investor relations section of the Altamunion website. Before we begin, I'd like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altamune cautions that these forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those indicated. For a review of the risk factors that could affect the company's future results and operations, we refer you to our filings with the SEC. I also direct...